Figure 4.

Antitumor efficacy of FL118 in individual mice with q2 x 5 schedules in human FaDu head-&-neck tumors(A, B) or SW620 colon (C, D) tumors in SCID mouse xenograft models: Tumor models are established as describedin the Methods. Treatment was initiated 7 days after subcutaneous tumor implantation (day 0), on which tumor sizewas about 200 - 250 mm³. FL118 in the Tween 80-free formulation was administrated using i.v. routes on day 0 atthe doses and schedules shown (arrowed). A and B. Anti-FaDu tumor activity of FL118 at the dose of 1.5 mg/kg and2.5 mg/kg with the schedule of every other day for five times (q2 x 5). C and D. Anti-SW620 tumor activity of FL118at the dose of 1.5 mg/kg and 2.5 mg/kg with q2 x 5 schedules.